315707-69-8

Basic information

• Product Name: 2-(3,4-difluorobenzamido)acetic acid
• Synonyms: 2-(3,4-difluorobenzamido)acetic acid
• CAS NO: 315707-69-8
• Molecular Weight: 215.156
• Mol File: 315707-69-8.mol
• Article Data: 2

Chemical Properties

• CAS DataBase Reference: 2-(3,4-difluorobenzamido)acetic acid(CAS DataBase Reference)
• NIST Chemistry Reference: 2-(3,4-difluorobenzamido)acetic acid(315707-69-8)
• EPA Substance Registry System: 2-(3,4-difluorobenzamido)acetic acid(315707-69-8)

Safety Data

• Hazardous Substances Data: 315707-69-8(Hazardous Substances Data)

Usage

Structure

A chemical compound containing a benzamido group and two fluorine atoms attached to the benzene ring, derived from acetic acid.

Usage

Commonly used in pharmaceutical research and development, particularly in the synthesis of potential drugs and medicinal compounds.

Applications

May have applications in the fields of organic chemistry and biochemistry.

Properties and reactivity

The presence of the benzamido and fluorine groups may impart specific properties and reactivity that make it useful for various scientific and industrial purposes.

Upstream product

• 76903-88-3 3,4-difluorobenzoyl chloride 
• 56-40-6 glycine 

Downstream Products

• 1229007-73-1 2-(3,4-difluorophenyl)oxazol-5(4H)-one 

Relevant articles and documents

Synthesis and evaluation of new phenyl acrylamide derivatives as potent non-nucleoside anti-HBV agents

As a continuation of our previous work, a series of new phenyl acrylamide derivatives (4Aa-g, 4Ba-t, 5 and 6a-c) were designed and synthesized as non-nucleoside anti-HBV agents. Among them, compound 4Bs could potently inhibit HBV DNA replication in wild-type and lamivudine (3TC)/entecavir resistant HBV mutant strains with IC50 values of 0.19 and 0.18 μM, respectively. Notably, the selective index value of 4Bs was above 526, indicating the favorable safety profile. Interestingly, unlike nucleoside analogue 3TC, 4Bs could significantly inhibit 3.5 kb pgRNA expression. Molecular docking study revealed that 4Bs could fit well into the dimer-dimer interface of HBV core protein by hydrophobic, π–π and H-bond interactions. Considering the potent anti-HBV activity, low toxicity and diverse anti-HBV mechanism from that of nucleoside anti-HBV agent 3TC, compound 4Bs might be a promising lead to develop novel non-nucleoside anti-HBV therapeutic agents, and warranted further investigation.